PubMed:33754144 / 1713-1915 JSONTXT

Annnotations TAB JSON ListView MergeView

    Inflammaging

    {"project":"Inflammaging","denotations":[{"id":"T17","span":{"begin":0,"end":202},"obj":"Sentence"},{"id":"T17","span":{"begin":0,"end":202},"obj":"Sentence"}],"text":"At day 14, 12 (57%) patients in the mavrilimumab group were alive and off supplemental oxygen therapy compared with nine (47%) patients in the placebo group (odds ratio 1·48 [95% CI 0·43-5·16]; p=0·76)."}

    yangbin123xm_800_3

    {"project":"yangbin123xm_800_3","denotations":[{"id":"T8","span":{"begin":36,"end":48},"obj":"CI"},{"id":"T13","span":{"begin":143,"end":150},"obj":"CI"}],"text":"At day 14, 12 (57%) patients in the mavrilimumab group were alive and off supplemental oxygen therapy compared with nine (47%) patients in the placebo group (odds ratio 1·48 [95% CI 0·43-5·16]; p=0·76)."}

    chenxin_473849_800_3

    {"project":"chenxin_473849_800_3","denotations":[{"id":"T14","span":{"begin":143,"end":150},"obj":"CI"},{"id":"T9","span":{"begin":36,"end":48},"obj":"CI"}],"text":"At day 14, 12 (57%) patients in the mavrilimumab group were alive and off supplemental oxygen therapy compared with nine (47%) patients in the placebo group (odds ratio 1·48 [95% CI 0·43-5·16]; p=0·76)."}